Antimicrobials
Meropenem

Meropenem

Medium
N/A

General Information

HEALTH CANADA APPROVED

  • Treatment of various infections due to susceptible organisms, including the following: lower respiratory tract, skin and soft tissue, intra-abdominal, gynecological, meningitis and bacteremia

Compromised renal function and/or CNS lesions; potential to cause seizures

  • Valproic acid serum concentrations may be reduced to subtherapeutic levels, resulting in a loss of seizure control. Monitor levels.
  • If administration of meropenem is necessary, supplemental anticonvulsant therapy should be considered.

LOCAL REACTIONS

  • Inflammation at injection site, thrombophlebitis

HYPERSENSITIVITY

  • Anaphylaxis, including bronchospasm and hypotension (rare)
  • Urticaria, pruritus

GASTROINTESTINAL

  • Nausea and vomiting, diarrhea
  • Pseudomembranous colitis (rare)

MISCELLANEOUS

  • Headache, rash
  • Seizures

IM or subcutaneous use: no information available at this time

Antimicrobial class: Carbapenem, beta-lactam

Pregnancy category: B

Average serum half life: 1 hour

Biliary penetration: Therapeutic

CSF penetration: Moderate

Lung penetration: Therapeutic

Urine penetration: Therapeutic

pH: 7.3 to 8.3